ICCM -
IceCure Medical Ltd. Ordinary Shares
| Day |
1m |
10m |
60m |
PreMarket |
Market |
AfterHours |
Gap |
| 0.64 0.03 (4.13%) |
0.0 (0.0%) |
-0.01 (-1.27%) |
0.01 (1.71%) |
0.0 (-0.74%) |
0.03 (5.07%) |
0.01 (2.0%) |
0.01 (1.01%) |
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
Earnings & Ratios
- Basic EPS:
- Diluted EPS:
- Basic P/E:
- Diluted P/E:
- RSI(14) 1m:
- 37.78
- VWAP:
- 0.67
- RVol:
Events
| Period |
Kind |
Movement |
Occurred At |
Related News
IceCure's ProSense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer
Nov 18, 2025 13:30
IceCure's Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival
Nov 03, 2025 13:30
IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances
Oct 13, 2025 12:30
IceCure Medical to Attend the 2025 Maxim Growth Summit
Oct 09, 2025 12:30
IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care
Oct 03, 2025 16:28
IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above
Oct 03, 2025 16:19
IceCure's ProSense® at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented
Sep 30, 2025 12:30
IceCure Granted Notice of Allowance for U.S. Patent for its Next-Generation XSense™ Cryoprobes
Sep 18, 2025 12:30
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals
Sep 16, 2025 16:29
IceCure's ProSense® Substantially Reduces Abdominal Wall Endometriosis Pain with High Procedural Efficacy
Sep 04, 2025 12:30